Archives of Virology

, Volume 155, Issue 9, pp 1371–1381 | Cite as

100 years poliovirus: from discovery to eradication. A meeting report

  • Tim SkernEmail author
Brief Review


Just over hundred years ago, Karl Landsteiner and Erwin Popper identified a virus, later termed poliovirus, as the causative agent of poliomyelitis. This groundbreaking discovery simultaneously provided the basis for the measures that today prevent the outbreaks of the terrible epidemics caused by poliovirus. In 1988, the WHO started its eradication program to eliminate the virus from the planet. The symposium celebrated the discovery of poliovirus and discussed our current state of knowledge of poliovirus biology. Prospects for the eradication program were evaluated, with particular emphasis being placed on why certain countries still have not succeeding in interrupting wild-type transmission of poliovirus. Discussion also centred on the role of inactivated poliovirus vaccines in the eradication program and the maintenance of a poliovirus-free world, whenever this goal should be achieved.


Poliomyelitis Eradication Program Acute Flaccid Paralysis Eradication Campaign Inactivate Poliovirus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



I thank Dieter Blaas, Franz X. Heinz and Jutta Steinberger for critical reading. The organisers thank the following institutions for their support in making the symposium possible: Austrian Academy of Sciences, Baxter, Austrian Ministries of Health and Science, GlaxoSmithKline, Austrian Society for Hygiene, Microbiology and Preventative Medicine, Intercell AG, Max F. Perutz Laboratories, Medical University of Vienna, Novartis Vaccines, Austrian Association of Molecular Life Sciences and Biotechnology, Rotary Club Austria, Sanofi Pasteur MSD, City of Vienna Science and Research Municipal Dept 7.


  1. 1.
    Agol VI, Schirman GA (1964) Interaction of guanidine-sensitive and guanidine-dependent variants of poliovirus in mixedly infected cells. Biochem Biophys Res Commun 17:28–33CrossRefGoogle Scholar
  2. 2.
    Brandenburg B, Lee LY, Lakadamyali M, Rust MJ, Zhuang X, Hogle JM (2007) Imaging poliovirus entry in live cells. PLoS Biol 5:e183PubMedCrossRefGoogle Scholar
  3. 3.
    Cello J, Paul A, Wimmer E (2002) Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297:1016–1018PubMedCrossRefGoogle Scholar
  4. 4.
    Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S (2008) Virus attenuation by genome-scale changes in codon pair bias. Science 320:1784–1787PubMedCrossRefGoogle Scholar
  5. 5.
    Cords CE, Holland JJ (1964) Replication of poliovirus RNA induced by heterologous virus. Proc Natl Acad Sci USA 51:1080–1082PubMedCrossRefGoogle Scholar
  6. 6.
    Dauer CC (1955) The changing age distribution of paralytic poliomyelitis. Ann N Y Acad Sci 61:943–955PubMedCrossRefGoogle Scholar
  7. 7.
    Dayan GH, Thorley M, Yamamura Y, Rodriguez N, McLaughlin S, Torres LM, Seda A, Carbia M, Alexander LN, Caceres V, Pallansch MA (2007) Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 195:12–20PubMedCrossRefGoogle Scholar
  8. 8.
    Dulbecco R (1952) Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci USA 38:747–752PubMedCrossRefGoogle Scholar
  9. 9.
    Dulbecco R, Vogt M (1958) Studies on the induction of mutations in poliovirus by proflavin. Virology 5:236–243PubMedCrossRefGoogle Scholar
  10. 10.
    Enders JF, Weller TH, Robbins FC (1949) Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109:85–87PubMedCrossRefGoogle Scholar
  11. 11.
    Francis TJ Jr, Napier JA, Voight R, Hemphill FM, Wenner HA, Korns RF, Boisen M, Tolchinsky E, Diamond EL (1957) Evaluation of the 1954 field trial of poliomyelitis vaccine. School of Public Health, University of Michigan, Ann ArborGoogle Scholar
  12. 12.
    Gmyl AP, Pilipenko EV, Maslova SV, Belov GA, Agol VI (1993) Functional and genetic plasticities of the poliovirus genome—quasi-infectious RNAs modified in the 5′-untranslated region yield a variety of pseudorevertants. J Virol 67:6309–6316PubMedGoogle Scholar
  13. 13.
    Grassly NC, Fraser C, Wenger J, Deshpande JM, Sutter RW, Heymann DL, Aylward RB (2006) New strategies for the elimination of polio from India. Science 314:1150–1153PubMedCrossRefGoogle Scholar
  14. 14.
    Hemmes JH, Winkler KC, Kool SM (1962) Virus survival as a seasonal factor in influenza and poliomyelitis. Antonie Van Leeuwenhoek 28:221–233PubMedCrossRefGoogle Scholar
  15. 15.
    Jang SK, Krausslich HG, Nicklin MJ, Duke GM, Palmenberg AC, Wimmer E (1988) A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol 62:2636–2643PubMedGoogle Scholar
  16. 16.
    Kew OM, Nottay BK (1984) Molecular epidemiology of polioviruses. Rev Infect Dis 6(Suppl 2):S499–S504PubMedCrossRefGoogle Scholar
  17. 17.
    Kiehn ED, Holland JJ (1970) Synthesis and cleavage of enterovirus polypeptides in mammalian cells. J Virol 5:358–367PubMedGoogle Scholar
  18. 18.
    Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, Hanecak R, Lee JJ, van der Werf S, Anderson CW, Wimmer E (1981) Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291:547–553PubMedCrossRefGoogle Scholar
  19. 19.
    Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, Kew OM, Agol VI (2003) Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol 77:12460–12465PubMedCrossRefGoogle Scholar
  20. 20.
    Landsteiner K, Popper E (1909) Übertragung der Poliomyelitis acuta auf Affen. Z Immunitätsforsch 2:377–390Google Scholar
  21. 21.
    Landsteiner K, Levaditi C (1909) La transmission de la paralysie infantile aux singes. C R Soc Biol 67:592–594Google Scholar
  22. 22.
    Landsteiner K, Levaditi C (1910) Recherches sur la paralysie infantile expérimentale. C R Acad Sci 150:131–132Google Scholar
  23. 23.
    Lavinder CH, Freeman AW, Frost WH (1918) Epidemiologic studies of poliomyelitis in New York City and the northeastern United States during the year 1916. Government Printing Office, Washington, DCGoogle Scholar
  24. 24.
    Ledinko N (1963) Genetic recombination with poliovirus type 1. Studies of crosses between a normal horse serum-resistant mutant and several guanidine-resistant mutants of the same strain. Virology 20:107–119PubMedCrossRefGoogle Scholar
  25. 25.
    Levy HC, Bostina M, Filman DJ, Hogle JM (2010) Catching a virus in the act of RNA release: a novel poliovirus uncoating intermediate characterized by cryo-electron microscopy. J Virol 84:4426–4441PubMedCrossRefGoogle Scholar
  26. 26.
    MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, O’Leary P, Thompson RA, Osman H, Wood P, Minor P, Wood DJ, Pillay D (2004) Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509–1513PubMedCrossRefGoogle Scholar
  27. 27.
    Maizel JV Jr (1964) Preparative electrophoresis of proteins in acrylamide gels. Ann N Y Acad Sci 121:382–390PubMedCrossRefGoogle Scholar
  28. 28.
    Minor P (2009) Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine 27:2649–2652PubMedCrossRefGoogle Scholar
  29. 29.
    Molla A, Paul AV, Wimmer E (1991) Cell-free, de novo synthesis of poliovirus. Science 254:1647–1651PubMedCrossRefGoogle Scholar
  30. 30.
    Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, Herrington JE, Pallansch MA, Patriarca PA (1993) Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 341:1545–1550PubMedCrossRefGoogle Scholar
  31. 31.
    Mueller JE, Bessaud M, Huang QS, Martinez LC, Barril PA, Morel V, Balanant J, Bocacao J, Hewitt J, Gessner BD, Delpeyroux F, Nates SV (2009) Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Cordoba Province, Argentina. Appl Environ Microbiol 75:1395–1401PubMedCrossRefGoogle Scholar
  32. 32.
    Nathanson N, Martin JR (1979) The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol 110:672–692PubMedGoogle Scholar
  33. 33.
    Nathanson N (1984) Epidemiologic aspects of poliomyelitis eradication. Rev Infect Dis 6(Suppl 2):S308–S312PubMedCrossRefGoogle Scholar
  34. 34.
    Nkowane BM, Wassilak SG, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, Kew OM (1987) Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. Jama 257:1335–1340PubMedCrossRefGoogle Scholar
  35. 35.
    Odoom JK, Yunus Z, Dunn G, Minor PD, Martin J (2008) Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient. J Virol 82:9179–9190PubMedCrossRefGoogle Scholar
  36. 36.
    Pelletier J, Sonenberg N (1988) Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334:320–325PubMedCrossRefGoogle Scholar
  37. 37.
    Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100:7289–7294PubMedCrossRefGoogle Scholar
  38. 38.
    Pilipenko EV, Gmyl AP, Maslova SV, Svitkin YV, Sinyakov AN, Agol VI (1992) Prokaryotic-like cis elements in the cap-independent internal initiation of translation on picornavirus RNA. Cell 68:119–131PubMedCrossRefGoogle Scholar
  39. 39.
    Racaniello VR, Baltimore D (1981) Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci USA 78:4887–4891PubMedCrossRefGoogle Scholar
  40. 40.
    Racinello VR, Baltimore D (1981) Cloned poliovirus complementary DNA is infectious im mammalian cells. Science 214:916–919CrossRefGoogle Scholar
  41. 41.
    Robbins FC, Enders JF, Weller TH (1950) The effect of poliomyelitis virus upon cells in tissue cultures. J Clin Invest 29:841PubMedGoogle Scholar
  42. 42.
    Roberts L (2009) Public health. Type 2 poliovirus back from the dead in Nigeria. Science 325:660–661PubMedCrossRefGoogle Scholar
  43. 43.
    Romanova LI, Tolskaya EA, Kolesnikova MS, Agol VI (1980) Biochemical evidence for intertypic genetic recombination of polioviruses. FEBS Lett 118:109–112PubMedCrossRefGoogle Scholar
  44. 44.
    Steere RL, Schaffer FL (1958) The structure of crystals of purified Mahoney poliovirus. Biochim Biophys Acta 28:241–246PubMedCrossRefGoogle Scholar
  45. 45.
    Stickle G (1964) Observed and expected poliomyelitis in the United States, 1958–1961. Am J Public Health Nations Health 54:1222–1229PubMedCrossRefGoogle Scholar
  46. 46.
    Vaughan JC, Brandenburg B, Hogle JM, Zhuang X (2009) Rapid actin-dependent viral motility in live cells. Biophys J 97:1647–1656PubMedCrossRefGoogle Scholar
  47. 47.
    Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R (2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344–348PubMedCrossRefGoogle Scholar
  48. 48.
    Wimmer E, Mueller S, Tumpey TM, Taubenberger JK (2009) Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat Biotechnol 27:1163–1172PubMedCrossRefGoogle Scholar
  49. 49.
    Wringe A, Fine PE, Sutter RW, Kew OM (2008) Estimating the extent of vaccine-derived poliovirus infection. PLoS One 3:e3433PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Max F. Perutz LaboratoriesMedical University of ViennaViennaAustria

Personalised recommendations